Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics (NASDAQ:VKTX).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Viking Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 80%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $63,900, and 9, calls, for a total amount of $718,259.
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $90.0 for Viking Therapeutics during the past quarter.
In today's trading context, the average open interest for options of Viking Therapeutics stands at 1655.67, with a total volume reaching 2,742.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Viking Therapeutics, situated within the strike price corridor from $55.0 to $90.0, throughout the last 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
VKTX | CALL | TRADE | BULLISH | 05/17/24 | $3.1 | $2.9 | $3.1 | $75.00 | $310.0K | 2.2K | 10 |
VKTX | CALL | SWEEP | BEARISH | 04/19/24 | $10.8 | $10.2 | $10.2 | $55.00 | $106.0K | 4.7K | 242 |
VKTX | CALL | TRADE | NEUTRAL | 05/17/24 | $3.1 | $2.9 | $3.0 | $75.00 | $75.0K | 2.2K | 1.0K |
VKTX | CALL | TRADE | BEARISH | 04/19/24 | $11.3 | $10.1 | $10.3 | $55.00 | $69.0K | 4.7K | 112 |
VKTX | PUT | SWEEP | BEARISH | 04/19/24 | $1.0 | $0.75 | $1.0 | $65.00 | $63.9K | 1.8K | 699 |
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In the last month, 4 experts released ratings on this stock with an average target price of $122.75.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, Benzinga Pro gives you real-time options trades alerts.
Posted In: VKTX